Aquestive Therapeutics Charts Cautious, Liquid Path Forward

Aquestive Therapeutics, Inc. ((AQST)) has held its Q1 earnings call. Read on for the main highlights of the call.

Aquestive Therapeutics Strikes Upbeat Tone As It Tightens Finances And Advances Anaphylm Toward Resubmission. Management highlighted a clear regulatory roadmap, markedly better quarterly numbers, and ample liquidity, while conceding that FDA requirements, reimbursement hurdles, and ongoing losses still pose meaningful execution risks.

Regulatory Progress Toward Anaphylm Resubmission

Aquestive reported steady momentum with regulators, including a Type A face‑to‑face meeting with the FDA and a teleconference with the U.K. MHRA. The company has filed a pediatric plan with the EMA and submitted its human factors protocol to the FDA, aiming for human factors and possibly PK data by August and a Q3 2026 NDA resubmission on a six‑month Type 2 review path.

Significant Improvement in Q1 Financial Performance

First‑quarter revenue jumped about 66% year over year to $14.4 million, with both manufacturing and licensing streams contributing. The net loss shrank to $8.1 million and non‑GAAP adjusted EBITDA loss tightened to $1.7 million, underscoring a sharp improvement in the company’s operating performance versus the prior year.

Strengthened Liquidity And Financing Flexibility

Aquestive bolstered its balance sheet with a $150 million Oaktree debt facility that refinances existing borrowings on better terms and extends the interest‑only period. Together with an extended RTW funding agreement, the company finished Q1 with roughly $110 million in cash and projects more than $150 million available at Anaphylm’s launch.

AQST‑108 Phase I Safety And Biomarker Signal

In dermatology, the company completed a Phase I safety study of AQST‑108 in men with androgenic alopecia and reported no drug‑related adverse events or meaningful systemic absorption. Management pointed to a directional biomarker shift in TSLP in treated subjects versus placebo, hinting at broader topical immunomodulatory potential, even though the trial was not powered for statistical proof.

Commercial Preparation And Medical Affairs Momentum

Commercial build‑out for Anaphylm is accelerating, with plans for a 75‑person U.S. sales force and a robust hub and patient‑support infrastructure. Medical affairs teams are targeting more than 40 conferences and over 20 publications in 2026, and market research shows health‑care‑provider awareness roughly doubling to about two‑thirds of the target audience.

Disciplined Expense Management

Operating discipline was another focus, as R&D expenses fell roughly 22% to $4.2 million and SG&A dropped about 42% to $11 million versus last year. The declines, driven by lower Anaphylm trial costs and reduced legal and commercial spending, played a key role in narrowing both the net loss and adjusted EBITDA deficit.

CRL And Remaining FDA Requirements

Investors were reminded that a January Complete Response Letter requires completion of a human factors validation study and a new PK study before Anaphylm can be approved. Management still expects a Type 2, six‑month review once it resubmits, but stressed that timing depends on FDA feedback and the agency’s pace in clearing study protocols and reviewing new data.

Coverage, Reimbursement And Physician‑Office Friction

The call emphasized that payer coverage and reimbursement could slow initial uptake, as plans may impose prior authorizations and other hurdles. Aquestive plans to counter this “friction” with heavy investment in hub services and aggressive negotiations with payers and PBMs to simplify office workflows and improve early patient access.

One‑Time Nature Of Q1 License And Royalty Boost

Management cautioned that the surge in license and royalty revenue to $5.4 million was largely driven by a single payment tied to a partner’s asset sale. That disclosure signals that investors should expect some lumpiness in top‑line results and not extrapolate the first‑quarter level as a sustainable run rate.

Conditional Access To Full Debt Facility

While the new Oaktree facility materially enhances liquidity, only the initial tranche was immediately drawn, with later tranches tied to regulatory and commercial milestones. Additional funding depends on FDA approval, sales thresholds, and mutual consent, meaning that actual leverage capacity will track the company’s execution over time.

Ongoing Losses And Adjusted EBITDA Outlook

Despite the quarter’s improvement, Aquestive remains loss‑making and does not expect to break even this year. Management guided to a 2026 non‑GAAP adjusted EBITDA loss of roughly $30 million to $35 million, underscoring that eventual profitability hinges on a timely approval and successful launch of Anaphylm.

Reduced R&D Spend And Development Timing

Lower R&D spending mainly reflected reduced Anaphylm trial activity while the company works through CRL‑driven requirements. That cutback boosts short‑term financials but also highlights that some development work is effectively paused until new FDA‑mandated studies can proceed, adding timing uncertainty to the pipeline.

Forward‑Looking Guidance And Launch Readiness

Looking ahead, Aquestive expects FDA feedback on its human factors protocol within weeks and aims to generate human factors and potentially PK data by its August update, supporting a planned Q3 2026 resubmission of the Anaphylm NDA. Financially, the firm reaffirmed 2026 guidance of $46 million to $50 million in revenue and a non‑GAAP adjusted EBITDA loss of $30 million to $35 million, while projecting over $150 million in cash at launch, assuming successful access to planned funding sources.

Aquestive’s earnings call painted a picture of a company tightening its finances, clarifying its regulatory path, and investing in a focused launch strategy despite lingering risks. For investors, the story now hinges on flawless execution of FDA‑mandated studies, timely review outcomes, and the company’s ability to convert its preparations into a profitable commercial franchise.